Independent research on the small and mid-cap public companies that rarely get a careful read.
The Q2 2026 print is the quarter Aurora moved from demonstration to industrial scaling. Revenue of $2 million (vs $1 million in Q2 2025) and a quarterly net loss of $270 million both look small in absolute terms; what…
Aurinia's second quarter looked like a single-product lupus drug stepping on the gas. Total revenue of $83.2 million was 19% above the year-ago $70.0 million; net product sales of LUPKYNIS hit $79.4 million, up 19% on…
AUNA's first quarter under fresh disclosure discipline arrived with two readings, and the right one is buried. Reported net income collapsed 75% year over year to S/9 million (S/0.09 per share, or roughly $0.03), and…
